The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. has announced a change in its major holdings, with BlackRock, Inc. increasing its voting rights in the company to 7.73%. This adjustment in BlackRock’s stake, which was previously 7.70%, reflects a minor yet significant shift in shareholder composition, potentially impacting MaxCyte’s strategic decisions and market perception.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on providing cell-engineering platforms that enable the development of advanced therapeutics. The company is known for its proprietary technology used in the creation of cell-based medicines, targeting a range of diseases.
YTD Price Performance: -40.43%
Average Trading Volume: 34,071
Technical Sentiment Signal: Buy
Current Market Cap: £204.2M
See more data about MXCT stock on TipRanks’ Stock Analysis page.